Last reviewed · How we verify
Drug-induced osteoporosis — Treatment Landscape & Competitive Intelligence
1 marketed
0 Phase 3
0 Phase 2
Live · 30-min refresh
Marketed treatment landscape
| Drug | Generic | Sponsor | Class | Target | Line of therapy | First approval |
|---|---|---|---|---|---|---|
| Prolia | DENOSUMAB | Amgen | RANK Ligand Inhibitor [EPC] | Tumor necrosis factor ligand superfamily member 11 | 2010-01-01 |
Phase 3 pipeline
Phase 2 pipeline
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Sponsor landscape
- Amgen · 1 drug in Drug-induced osteoporosis
Subscribe to ongoing alerts
Every new regulatory action, PDUFA date, or trial completion in Drug-induced osteoporosis:
- Drug-induced osteoporosis treatment updates — RSS
- Drug-induced osteoporosis treatment updates — Atom
- Drug-induced osteoporosis treatment updates — JSON
Cite this brief
Drug Landscape (2026). Drug-induced osteoporosis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/drug-induced-osteoporosis. Accessed 2026-06-10.
Related
- Drug-induced osteoporosis full disease profile — treatment pathway, diagnostics, guidelines
- Browse all CI briefs
- Build a custom feed
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing